Edwards Lifesciences Corp
Edwards Lifesciences Corp/ US28176E1082 /
EW
|
2024-05-20 9:59:54 PM
|
Chg.
+0.69
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
89.80USD
|
+0.77%
|
68,917
Turnover: 6.17 mill. |
-Bid Size: - |
-Ask Size: - |
54.1 bill.USD |
- |
38.87 |
Fundamentals
| |
FY 2023 |
Growth (1Y) |
| Per Share |
|
| Earnings per Share: |
2.31 USD |
-6.10% |
| EPS Diluted: |
2.30 USD |
-5.74% |
| Revenues per Share: |
9.99 USD |
12.86% |
| Book Value per Share: |
11.17 USD |
17.07% |
| Cash Flow per Share: |
1.49 USD |
-25.61% |
| Dividend per Share: |
- USD |
- |
| Total |
in mill. |
|
| Revenues: |
6,004.80 USD |
11.56% |
| Net Income: |
1,402.40 USD |
-7.85% |
| Operating Cash Flow: |
895.80 USD |
- |
| Cash and Cash Equivalents: |
1,144.00 USD |
- |
Valuation Ratios
| |
Current |
Latest FY* |
| P/E Ratio: |
38.87 |
33.01 |
| P/S Ratio: |
8.99 |
7.64 |
| P/BV ratio: |
8.03 |
6.82 |
| P/CF Ratio: |
60.26 |
51.18 |
| PEG: |
-6.37 |
-5.41 |
| Earnings Yield: |
2.57% |
3.03% |
| Dividend Yield: |
- |
- |
| Market Capitalization |
|
| Market Capitalization: |
54.1 bill. USD |
45.85 bill. USD |
| Free Float Market Cap.: |
- USD |
- USD |
| Market Cap. / Employee: |
- USD |
- USD |
| Shares Outstanding: |
602.6 mill. |
|
Profitability
| Gross Profit Margin: |
77.02% |
| EBIT Margin: |
25.55% |
| Net Profit Margin: |
23.35% |
| Return on Equity: |
20.87% |
| Return on Assets: |
14.98% |
Financial Strength
| Liquidity I / Cash Ratio: |
95.70% |
| Liquidity II / Quick Ratio: |
160.54% |
| Liquidity III / Current Ratio: |
337.60% |
| Debt / Equity Ratio: |
39.35% |
| Dynam. Debt / Equity Ratio: |
295.13% |
Efficiency
| Employees: |
- |
| Personal Expenses / Employee: |
- USD |
| Revenues / Employee: |
- USD |
| Net Income / Employee: |
- USD |
| Total Assets / Employee: |
- USD |
| * Fiscal Year End: |
2023-12-31 |
| Accounting Standard: |
US GAAP |
